Fuhrman Alan
SEC-identified person · CIK 1303521 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Tyra Biosciences, Inc. TYRA | Chief Financial Officer | filed 2023 - 2026 |
| Springworks Therapeutics, Inc. [SWTX | Director | filed 2019 - 2025 |
| Esperion Therapeutics, Inc. ESPR | Director | filed 2020 - 2024 |
| Checkmate Pharmaceuticals, Inc. CMPI | Director · See Remarks | filed 2020 - 2022 |
| Loxo Oncology, Inc. LOXO | Director | filed 2015 - 2019 |
| Synlogic, INC. SYBX | Chief Financial Officer | filed 2015 - 2016 |
| Ambit Biosciences Corp AMBI | Chief Financial Officer | filed 2013 - 2014 |
| Sonus Pharmaceuticals INC ogxi | Senior Vice President & CFO | filed 2006 - 2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.